Showing 14,081 - 14,100 results of 102,184 for search '(( 5 nn decrease ) OR ( 5 ((((we decrease) OR (a decrease))) OR (mean decrease)) ))', query time: 1.77s Refine Results
  1. 14081
  2. 14082
  3. 14083
  4. 14084
  5. 14085

    DataSheet1_Decreasing acid value of fatty acid ethyl ester products using complex enzymes.PDF by Yuting Li (524325)

    Published 2024
    “…The optimal reaction conditions were: 1% addition of liquid lipase Eversa<sup>®</sup> Transform 2.0% and 0.8% of enzyme dry powder CALB, reaction temperature 35°C, alcohol-oil ratio 9:1 (mol/mol), 0.8 g/g of 4A-MS and reaction time 24 h. Under the optimal reaction conditions, the FAEE yield was 90.8% ± 1.5% and its acid value was decreased from 12.0 ± 0.2 mgKOH/g to 0.39 ± 0.10 mgKOH/g. …”
  6. 14086
  7. 14087

    DataSheet_4_RNA Demethylase ALKBH5 Prevents Lung Cancer Progression by Regulating EMT and Stemness via Regulating p53.zip by Xiangli Liu (507857)

    Published 2022
    “…Knockdown of ALKBH5 increased global m<sup>6</sup>A level, and also increased E-cadherin, decreased stem hallmarkers, Nanog and Oct4, and inhibited stemness of CSCs. …”
  8. 14088

    DataSheet_3_RNA Demethylase ALKBH5 Prevents Lung Cancer Progression by Regulating EMT and Stemness via Regulating p53.zip by Xiangli Liu (507857)

    Published 2022
    “…Knockdown of ALKBH5 increased global m<sup>6</sup>A level, and also increased E-cadherin, decreased stem hallmarkers, Nanog and Oct4, and inhibited stemness of CSCs. …”
  9. 14089

    DataSheet_6_RNA Demethylase ALKBH5 Prevents Lung Cancer Progression by Regulating EMT and Stemness via Regulating p53.zip by Xiangli Liu (507857)

    Published 2022
    “…Knockdown of ALKBH5 increased global m<sup>6</sup>A level, and also increased E-cadherin, decreased stem hallmarkers, Nanog and Oct4, and inhibited stemness of CSCs. …”
  10. 14090

    DataSheet_1_RNA Demethylase ALKBH5 Prevents Lung Cancer Progression by Regulating EMT and Stemness via Regulating p53.zip by Xiangli Liu (507857)

    Published 2022
    “…Knockdown of ALKBH5 increased global m<sup>6</sup>A level, and also increased E-cadherin, decreased stem hallmarkers, Nanog and Oct4, and inhibited stemness of CSCs. …”
  11. 14091

    DataSheet_2_RNA Demethylase ALKBH5 Prevents Lung Cancer Progression by Regulating EMT and Stemness via Regulating p53.zip by Xiangli Liu (507857)

    Published 2022
    “…Knockdown of ALKBH5 increased global m<sup>6</sup>A level, and also increased E-cadherin, decreased stem hallmarkers, Nanog and Oct4, and inhibited stemness of CSCs. …”
  12. 14092

    DataSheet_7_RNA Demethylase ALKBH5 Prevents Lung Cancer Progression by Regulating EMT and Stemness via Regulating p53.zip by Xiangli Liu (507857)

    Published 2022
    “…Knockdown of ALKBH5 increased global m<sup>6</sup>A level, and also increased E-cadherin, decreased stem hallmarkers, Nanog and Oct4, and inhibited stemness of CSCs. …”
  13. 14093

    Inhibition of PKA by siRNA increased cell proliferation and decreases apoptosis in endothelial cells under high glucose treatment. by Zhaoyun Zhang (118032)

    Published 2012
    “…<p>Cells were transfected with siRNA and then treated with 5.6 mM glucose or 25 mM glucose for 72 hours: A: siRNA enhanced cell proliferation under high glucose conditions B: siRNA decreased apoptosis under high glucose conditions. *, p<0.05 compared with 5.6 mM condition. n = 6.…”
  14. 14094

    Knockdown of OAMB or 5-HT<sub>1A</sub> in IPCs resulted in opposite phenotypes in a capillary feeding assay (CAFE). by Jiangnan Luo (218899)

    Published 2014
    “…<p><b>A</b> Diminishing 5-HT<sub>1A</sub> in IPCs (<i>Dilp2</i>-Gal4><i>5-HT<sub>1A</sub></i>-RNAi) significantly decreases food intake only during day 2. …”
  15. 14095
  16. 14096

    DataSheet1_Monoclonal Antibodies Targeting IL-5 or IL-5Rα in Eosinophilic Chronic Obstructive Pulmonary Disease: A Systematic Review and Meta-Analysis.DOCX by Chuchu Zhang (2562154)

    Published 2021
    “…</p><p>Results: Anti-IL-5 therapy was associated with a decrease in acute exacerbation rate (RR 0.89; 95% CI 0.84 to 0.95, I<sup>2</sup> = 0%) and the severe adverse events (RR 0.90; 95% CI 0.84 to 0.97, I<sup>2</sup> = 0%). …”
  17. 14097
  18. 14098
  19. 14099
  20. 14100